M. Coelho | Faculdade Pitágoras (original) (raw)
Papers by M. Coelho
European Journal of Cancer Supplements, 2008
The neuroradiology journal, Jan 15, 2011
The authors reviewed the diffusion tensor imaging (DTI) and tractography (DTT) of the normal brai... more The authors reviewed the diffusion tensor imaging (DTI) and tractography (DTT) of the normal brainstem and cerebellar white matter in normal volunteers, correlating it with structural magnetic resonance (MR) imaging and DTI data obtained in patients evaluated in our institution with movement disorders, including multisystem atrophy (MSA), spinocerebellar ataxia (SCA), progressive supra-nuclear palsy (PSP) and idiopathic Parkinson's disease (PD). DTI and tractography data demonstrated major white-matter fibers within the brain stem and cerebellum, including cortico-spinal tracts, transverse pontine fibers, medial lemniscus and cerebellar peduncles. Visualization of selective degeneration of these individual fibre tracts with DTI, in our cases, added qualitative data to the differential diagnosis of movement disorders.
Natural extracts are an attractive source of new compounds, not only owing to the diversity and n... more Natural extracts are an attractive source of new compounds, not only owing to the diversity and novelty of chemical structures, but also owing to their potential biological action. The potential applications of these extracts include cosmetic and pharmaceutical areas. The aim of this research is to encapsulate fruit and plant extracts with biological activities such as antioxidants. The need for
European Journal of Cancer Supplements, 2006
Case Reports, 2011
Neuroschistosomiasis caused by Schistosoma mansoni (Sm) is a rare and severe condition potentiall... more Neuroschistosomiasis caused by Schistosoma mansoni (Sm) is a rare and severe condition potentially leading to permanent neurological deficit. An 18-year-old Brazilian female was admitted due to a severe conus medullaris and cauda equina syndrome. MRI of thoracic/lumbar spine showed an expanded conus medullaris with patchy gadolinium-enhancement, needle electromyography revealed acute bilateral radiculopathy (L5-S1-S2), cerebrospinal fluid (CSF) showed lymphocytosis and increased proteins and lesion' surgical biopsy documented a lymphocyte infiltrate. Immunodiagnosis with cercariae hullen reaction using Sm cercariae in CSF and serum and immunoelectrodiffusion for circulating antigens detection using anti-Sm antibodies were positive. No schistosoma parasites were found. The patient was treated with praziquantel and corticotherapy for 6 months. At 1 month, partial clinical improvement was noticed, and MRI showed a normal size conus medullaris. At 6 months, there was complete clinical recovery. This case shows that a severe neurological deficit by Sm may have a clinical full recovery after treatment.
Nature Reviews Neurology, 2012
The cardinal symptoms of Parkinson disease (PD) are asymmetrical bradykinesia, rigidity, resting ... more The cardinal symptoms of Parkinson disease (PD) are asymmetrical bradykinesia, rigidity, resting tremor and postural instability. However, the presence and spectrum of, and disability caused by, nonmotor symptoms (NMS) are being increasingly recognized. NMS include dementia, psychosis, depression and apathy, and are a major source of disability in later stages of PD, in association with axial symptoms that are resistant to levodopa therapy. The model of clinical progression of PD should, therefore, incorporate NMS, instead of being restricted to motor signs and levodopa-induced motor complications. Patients with disabling motor complications are classified as having advanced PD, which has been thought to represent the ultimate stage of disease. However, deep brain stimulation to treat motor complications has dramatically changed this scenario, with implications for the definition of advanced-stage disease. As treatment improves and survival times increase, patients are increasingly progressing to a later phase of disease in which they are highly dependent on caregivers, and disability is dominated by motor symptoms and NMS that are resistant to levodopa. In this article, we review the changing landscape of the later stages of PD, and propose a definition of late-stage PD to designate patients who have progressed beyond the advanced stage.
Reviews, 1996
Page 1. Piribedil for symptomatic management of Parkinson's disease (Protocol) Neutel D,... more Page 1. Piribedil for symptomatic management of Parkinson's disease (Protocol) Neutel D, Ferreira J, Coelho MM, Rosa MM, Rascol O, Sampaio C This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane ...
Parkinsonism & Related Disorders, 2013
Journal of the Neurological Sciences, 2013
Journal of Neurology, Neurosurgery & Psychiatry, 2008
Journal of Neurology, 2008
Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum t... more Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum toxin (BTX) type A and B have been proposed as alternatives to traditional treatments. To evaluate the efficacy and safety of BTX type B in the treatment of sialorrhea in patients with bulbar-onset ALS. Open-label prospective study of BTX type B injections in parotids (1000 U) and submandibular (250 U) glands using anatomic landmarks. Primary outcome was rate of responders (improvement > 50% on visual analogue scales (VAS) of severity and disability of sialorrhea) 1 month post-treatment. Other outcomes included subjective (drooling and quality of daily living questionnaires) and objective (cotton roll weights and number of paper handkerchiefs used) evaluations. Safety evaluations included questionnaires regarding brain stem symptoms. Sixteen ALS patients were included. At 1 month the rate of responders was 75% with a mean reduction of 70% in severity and disabling VASs. Fifteen patients (94 %) reported some benefit with drooling reduction. In objective measurements there was a reduction over 60 % in saliva production and in the number of handkerchiefs used. Onset of effect occurred within 3 days. Most patients reported better quality of living. The most frequent side-effects were viscous saliva, local pain, chewing weakness and respiratory infection. There were no changes in blood pressure or cardiac rate. At 3 months, there was still a positive effect in all outcomes. All patients except one manifested their willingness to repeat treatment. Anatomic guided BTX type B injections seem effective and safe to treat sialorrhea in bulbar-onset ALS.
Journal of Neurology, 2010
Studies of late stages of Parkinson&a... more Studies of late stages of Parkinson's disease (LS-PD) are limited. To provide an adequate health plan for patients in these most advanced stages, accurate information on their clinical condition is necessary. We characterize clinical features and medication use of LS-PD. A cross-sectional study of LS-PD stage 4 or 5 of Hoehn and Yahr during on states is presented in this paper. Demographics, clinical features and medication data were obtained using a structured questionnaire and physical examination. Patients were asked to grade the perceived impact of symptoms on their health status. Fifty patients (mean age 74.1 years and mean disease duration 17.9 years) were studied. Severe akinetic symmetric parkinsonism was present in most, with negligible rigidity and tremor, and most patients were wheelchair-bound. Severe postural instability and freezing of gait, causing frequent falls and fractures, and prominent dysarthria and dysphagia dominated the motor syndrome. Levodopa remained effective in most patients in relieving motor symptoms including tremor. Motor fluctuations and dyskinesias were present in 78 and 62% of patients, respectively, but were not perceived as disabling. All had neuropsychiatric and dysautonomic symptoms. Visual hallucinations were present in 44%, depression in 62% and dementia in 50%. Lack of tremor (p < 0.01) and absence of depression (p < 0.01) were independently associated with dementia (R(2) = 45%). Symptoms causing greatest impact on perceived health status were falls, gait unsteadiness, urinary dysfunction and sweats. Motor and non-motor non-levodopa responsive problems were frequent and the main cause of disability. Fluctuations and dyskinesias were frequent though not disabling. Dementia is not unavoidable in these very late stages.
Expert Opinion on Pharmacotherapy, 2008
Late-stage Parkinson&... more Late-stage Parkinson's disease is characterised by patients dependent on caregivers for their activities of daily living, even under the best levodopa benefit. Non-motor signs that overcome the well-known motor signs of Parkinson's disease dominate late-stage Parkinson's disease and few systematic data exist for the treatment of these signs. The objective of this study was to review the treatment options for Parkinson's disease dementia, psychosis, falls, bone fractures, joint and skeletal deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and urological dysfunction in late-stage Parkinson's disease. The study analysed the available controlled clinical trials for the above medical conditions. When absent, data from case series and the authors' own experience was considered. Few controlled clinical trials specifically addressed late-stage Parkinson's disease as a target population. There is a need for therapeutic data on the symptoms that most afflict late-stage Parkinson's disease patients.
... que a los hombres (Frueh 1976; Grandas 1988; Henderson 1956; Jankovic 1983; Marsden 1976;Tolo... more ... que a los hombres (Frueh 1976; Grandas 1988; Henderson 1956; Jankovic 1983; Marsden 1976;Tolosa 1981). ... Sharpe 1974; Wickramasekera 1974), biorretroalimentación electromiográfica (Ballard 1972; Brantley 1985; Murphy 1984; Peck 1977; Rowan 1981; Stephenson ...
European Journal of Cancer Supplements, 2008
The neuroradiology journal, Jan 15, 2011
The authors reviewed the diffusion tensor imaging (DTI) and tractography (DTT) of the normal brai... more The authors reviewed the diffusion tensor imaging (DTI) and tractography (DTT) of the normal brainstem and cerebellar white matter in normal volunteers, correlating it with structural magnetic resonance (MR) imaging and DTI data obtained in patients evaluated in our institution with movement disorders, including multisystem atrophy (MSA), spinocerebellar ataxia (SCA), progressive supra-nuclear palsy (PSP) and idiopathic Parkinson's disease (PD). DTI and tractography data demonstrated major white-matter fibers within the brain stem and cerebellum, including cortico-spinal tracts, transverse pontine fibers, medial lemniscus and cerebellar peduncles. Visualization of selective degeneration of these individual fibre tracts with DTI, in our cases, added qualitative data to the differential diagnosis of movement disorders.
Natural extracts are an attractive source of new compounds, not only owing to the diversity and n... more Natural extracts are an attractive source of new compounds, not only owing to the diversity and novelty of chemical structures, but also owing to their potential biological action. The potential applications of these extracts include cosmetic and pharmaceutical areas. The aim of this research is to encapsulate fruit and plant extracts with biological activities such as antioxidants. The need for
European Journal of Cancer Supplements, 2006
Case Reports, 2011
Neuroschistosomiasis caused by Schistosoma mansoni (Sm) is a rare and severe condition potentiall... more Neuroschistosomiasis caused by Schistosoma mansoni (Sm) is a rare and severe condition potentially leading to permanent neurological deficit. An 18-year-old Brazilian female was admitted due to a severe conus medullaris and cauda equina syndrome. MRI of thoracic/lumbar spine showed an expanded conus medullaris with patchy gadolinium-enhancement, needle electromyography revealed acute bilateral radiculopathy (L5-S1-S2), cerebrospinal fluid (CSF) showed lymphocytosis and increased proteins and lesion' surgical biopsy documented a lymphocyte infiltrate. Immunodiagnosis with cercariae hullen reaction using Sm cercariae in CSF and serum and immunoelectrodiffusion for circulating antigens detection using anti-Sm antibodies were positive. No schistosoma parasites were found. The patient was treated with praziquantel and corticotherapy for 6 months. At 1 month, partial clinical improvement was noticed, and MRI showed a normal size conus medullaris. At 6 months, there was complete clinical recovery. This case shows that a severe neurological deficit by Sm may have a clinical full recovery after treatment.
Nature Reviews Neurology, 2012
The cardinal symptoms of Parkinson disease (PD) are asymmetrical bradykinesia, rigidity, resting ... more The cardinal symptoms of Parkinson disease (PD) are asymmetrical bradykinesia, rigidity, resting tremor and postural instability. However, the presence and spectrum of, and disability caused by, nonmotor symptoms (NMS) are being increasingly recognized. NMS include dementia, psychosis, depression and apathy, and are a major source of disability in later stages of PD, in association with axial symptoms that are resistant to levodopa therapy. The model of clinical progression of PD should, therefore, incorporate NMS, instead of being restricted to motor signs and levodopa-induced motor complications. Patients with disabling motor complications are classified as having advanced PD, which has been thought to represent the ultimate stage of disease. However, deep brain stimulation to treat motor complications has dramatically changed this scenario, with implications for the definition of advanced-stage disease. As treatment improves and survival times increase, patients are increasingly progressing to a later phase of disease in which they are highly dependent on caregivers, and disability is dominated by motor symptoms and NMS that are resistant to levodopa. In this article, we review the changing landscape of the later stages of PD, and propose a definition of late-stage PD to designate patients who have progressed beyond the advanced stage.
Reviews, 1996
Page 1. Piribedil for symptomatic management of Parkinson's disease (Protocol) Neutel D,... more Page 1. Piribedil for symptomatic management of Parkinson's disease (Protocol) Neutel D, Ferreira J, Coelho MM, Rosa MM, Rascol O, Sampaio C This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane ...
Parkinsonism & Related Disorders, 2013
Journal of the Neurological Sciences, 2013
Journal of Neurology, Neurosurgery & Psychiatry, 2008
Journal of Neurology, 2008
Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum t... more Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum toxin (BTX) type A and B have been proposed as alternatives to traditional treatments. To evaluate the efficacy and safety of BTX type B in the treatment of sialorrhea in patients with bulbar-onset ALS. Open-label prospective study of BTX type B injections in parotids (1000 U) and submandibular (250 U) glands using anatomic landmarks. Primary outcome was rate of responders (improvement > 50% on visual analogue scales (VAS) of severity and disability of sialorrhea) 1 month post-treatment. Other outcomes included subjective (drooling and quality of daily living questionnaires) and objective (cotton roll weights and number of paper handkerchiefs used) evaluations. Safety evaluations included questionnaires regarding brain stem symptoms. Sixteen ALS patients were included. At 1 month the rate of responders was 75% with a mean reduction of 70% in severity and disabling VASs. Fifteen patients (94 %) reported some benefit with drooling reduction. In objective measurements there was a reduction over 60 % in saliva production and in the number of handkerchiefs used. Onset of effect occurred within 3 days. Most patients reported better quality of living. The most frequent side-effects were viscous saliva, local pain, chewing weakness and respiratory infection. There were no changes in blood pressure or cardiac rate. At 3 months, there was still a positive effect in all outcomes. All patients except one manifested their willingness to repeat treatment. Anatomic guided BTX type B injections seem effective and safe to treat sialorrhea in bulbar-onset ALS.
Journal of Neurology, 2010
Studies of late stages of Parkinson&a... more Studies of late stages of Parkinson's disease (LS-PD) are limited. To provide an adequate health plan for patients in these most advanced stages, accurate information on their clinical condition is necessary. We characterize clinical features and medication use of LS-PD. A cross-sectional study of LS-PD stage 4 or 5 of Hoehn and Yahr during on states is presented in this paper. Demographics, clinical features and medication data were obtained using a structured questionnaire and physical examination. Patients were asked to grade the perceived impact of symptoms on their health status. Fifty patients (mean age 74.1 years and mean disease duration 17.9 years) were studied. Severe akinetic symmetric parkinsonism was present in most, with negligible rigidity and tremor, and most patients were wheelchair-bound. Severe postural instability and freezing of gait, causing frequent falls and fractures, and prominent dysarthria and dysphagia dominated the motor syndrome. Levodopa remained effective in most patients in relieving motor symptoms including tremor. Motor fluctuations and dyskinesias were present in 78 and 62% of patients, respectively, but were not perceived as disabling. All had neuropsychiatric and dysautonomic symptoms. Visual hallucinations were present in 44%, depression in 62% and dementia in 50%. Lack of tremor (p < 0.01) and absence of depression (p < 0.01) were independently associated with dementia (R(2) = 45%). Symptoms causing greatest impact on perceived health status were falls, gait unsteadiness, urinary dysfunction and sweats. Motor and non-motor non-levodopa responsive problems were frequent and the main cause of disability. Fluctuations and dyskinesias were frequent though not disabling. Dementia is not unavoidable in these very late stages.
Expert Opinion on Pharmacotherapy, 2008
Late-stage Parkinson&... more Late-stage Parkinson's disease is characterised by patients dependent on caregivers for their activities of daily living, even under the best levodopa benefit. Non-motor signs that overcome the well-known motor signs of Parkinson's disease dominate late-stage Parkinson's disease and few systematic data exist for the treatment of these signs. The objective of this study was to review the treatment options for Parkinson's disease dementia, psychosis, falls, bone fractures, joint and skeletal deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and urological dysfunction in late-stage Parkinson's disease. The study analysed the available controlled clinical trials for the above medical conditions. When absent, data from case series and the authors' own experience was considered. Few controlled clinical trials specifically addressed late-stage Parkinson's disease as a target population. There is a need for therapeutic data on the symptoms that most afflict late-stage Parkinson's disease patients.
... que a los hombres (Frueh 1976; Grandas 1988; Henderson 1956; Jankovic 1983; Marsden 1976;Tolo... more ... que a los hombres (Frueh 1976; Grandas 1988; Henderson 1956; Jankovic 1983; Marsden 1976;Tolosa 1981). ... Sharpe 1974; Wickramasekera 1974), biorretroalimentación electromiográfica (Ballard 1972; Brantley 1985; Murphy 1984; Peck 1977; Rowan 1981; Stephenson ...